Regeneron Pharmaceuticals Appoints George D. Yancopoulos as Chief Scientific Officer

Strategic Insights -

Regeneron Pharmaceuticals, Inc. has announced that George D. Yancopoulos, M.D., Ph.D., has been named the Company's Chief Scientific Officer, in addition to his role as Senior Vice President of Research. Dr. Yancopoulos joined Regeneron in 1989 and has led the Company's molecular and cell biology scientists in making numerous landmark discoveries and breakthroughs with potential clinical applications in neurodegenerative diseases, cancer, and revascularization of ischemic tissue. These discoveries formed the basis of Regeneron's collaboration with The Procter & Gamble Company. According to citation rankings compiled by the Institute for Scientific Information, Dr. Yancopoulos is the only industry scientist among the ten most highly cited researchers in biomedicine during the 1990s.

Key Takeaways:

  • George D. Yancopoulos, M.D., Ph.D., has been appointed as Regeneron's Chief Scientific Officer, in addition to his role as Senior Vice President of Research.
  • Dr. Yancopoulos joined Regeneron in 1989 and has led the Company's molecular and cell biology scientists in making numerous landmark discoveries and breakthroughs.
  • Regeneron's molecular and cell biology scientists have made significant progress in understanding the mechanisms of action of growth factors and their potential applications in treating various diseases.
  • The Company has a broad, long-term collaboration with The Procter & Gamble Company, which has contributed to its research and development efforts.
  • Regeneron is conducting human clinical studies of its brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) through its partnership with Amgen.
  • The Company has a number of research collaborations, including a long-term agreement with The Procter & Gamble Company.
  • Regeneron is developing protein-based and small-molecule drugs for the treatment of neurological, inflammatory, and muscle diseases, as well as abnormal bone growth, obesity, cancer, and angiogenesis.
  • The Company has announced that David M. Valenzuela, Ph.D., has been named Vice President, Genomics and Bioinformatics.

Statistics:

  • Regeneron's molecular and cell biology scientists have made a number of landmark discoveries and breakthroughs.
  • According to citation rankings compiled by the Institute for Scientific Information, Dr. Yancopoulos is the only industry scientist among the ten most highly cited researchers in biomedicine during the 1990s.
  • The Company has a broad, long-term collaboration with The Procter & Gamble Company, which has contributed to its research and development efforts.
  • Regeneron is conducting human clinical studies of its BDNF and NT-3 through its partnership with Amgen.

Sources:

  • Regeneron Pharmaceuticals, Inc. (1998). Regeneron Pharmaceuticals Appoints George D. Yancopoulos as Chief Scientific Officer. BW HealthWire.
  • Regeneron Pharmaceuticals, Inc. (1996). Form 10-K for the year ended December 31, 1996.
  • Regeneron Pharmaceuticals, Inc. (1998). Current Form 10-Q.